All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Susan O’Brien, MD, is Associate Director for Clinical Science at the Chao Family Comprehensive Cancer Center, Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, and Professor of Medicine at University of California Irvine, Irvine, US.
Professor O’Brien is an internationally recognized leader in the research of treatments for both chronic and acute leukemias and an acknowledged expert on several important treatments that are currently used as the standard of care for chronic lymphocytic leukemia. She has been closely involved with clinical research that has led to many key discoveries which have advanced the understanding and treatment of the disease. Prof. O’Brien is involved with multiple professional organizations, such as the American Society of Hematology, the American Society of Clinical Oncology, and the American Association for Cancer Research. She is a Hematology Member of the SWOG Executive Committee. She is also a Section Editor for Cancer and has authored and co-authored over 800 peer-reviewed articles.
Positions of responsibility/awards: